These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8390340)

  • 1. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
    Spicer DV; Pike MC; Pike A; Rude R; Shoupe D; Richardson J
    Contraception; 1993 May; 47(5):427-44. PubMed ID: 8390340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contraception and cancer prevention.
    Ursin G; Spicer DV; Pike MC
    Adv Contracept Deliv Syst; 1994; 10(3-4):369-86. PubMed ID: 12287845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
    Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
    J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pill-a-month as an oral contraceptive.
    Hefnawi F; Hassanein M; Younis N
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):1-17. PubMed ID: 12256024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera.
    Fotherby K; Benagiano G; Toppozada HK; Abdel-Rahman A; Navaroli F; Arce B; Ramos-Cordero R; Gual C; Landgren BM; Johannisson E
    Contraception; 1982 Mar; 25(3):261-72. PubMed ID: 6210485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use.
    Belsey EM
    Contraception; 1988 Aug; 38(2):207-25. PubMed ID: 2971506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menstrual impact of contraception.
    Stubblefield PG
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1513-22. PubMed ID: 8178900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
    Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
    J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contraceptive and endometrial effects of medroxyprogesterone acetate.
    Lee RA
    Am J Obstet Gynecol; 1969 May; 104(1):130-3. PubMed ID: 5777697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term estrogen replacement therapy. II. Neoplasia.
    Hammond CB; Jelovsek FR; Lee KL; Creasman WT; Parker RT
    Am J Obstet Gynecol; 1979 Mar; 133(5):537-47. PubMed ID: 220875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
    Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
    Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.